Caring Brands Inc. announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis’s over-the-counter (OTC) nausea relief product. The agreement provides Caring Brands with full rights to commercialise Emesyl and to oversee all manufacturing activities associated with the product.

Under the terms of the agreement, Caring Brands will assume responsibility for product manufacturing, marketing, sales strategy, and global distribution. Itonis will provide technical information, product formulation data, historical sales information, and intellectual property details to support Caring Brands’ commercial launch and ongoing development efforts.

According to QY Research, the global market for nausea treatment and related therapies is projected to exceed $6.23 billion in 2025, underscoring the broader commercial context for the Emesyl license.

Glynn Wilson, CEO of Caring Brands Inc., said, “Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognised product with real commercial potential, and we look forward to revitalising and scaling its market presence. This agreement aligns perfectly with our long-term strategy for OTC products, and we are excited to share more about our upcoming plans in the months ahead.”

The agreement includes a royalty structure based on future net sales, along with the potential for Caring Brands to earn equity in Itonis tied to revenue milestones. Caring Brands expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as these initiatives advance.